63
Participants
Start Date
June 3, 2021
Primary Completion Date
October 31, 2023
Study Completion Date
October 31, 2023
Investigational RSV vaccine MV-012-968 (Dosage 1)
Single dose administered intranasally on Day 1
Investigational RSV vaccine MV-012-968 (Dosage 2)
Single dose administered intranasally on Day 1
Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)
Single dose administered intranasally on Day 1
Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)
Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
Placebo (single-dose)
Single dose administered intranasally on Day 1
Placebo (two-dose)
Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
NOT_YET_RECRUITING
Coastal Pediatric Research, Summerville
RECRUITING
The Emory Children's Center, Atlanta
RECRUITING
Meridian Clinical Research, Binghamton
NOT_YET_RECRUITING
Aventiv Research, Columbus
RECRUITING
Meridian Clinical Research, Omaha
NOT_YET_RECRUITING
Meridian Clinical Research, Hastings
RECRUITING
MedPharmics, Metairie
RECRUITING
Benchmark Research, San Antonio
NOT_YET_RECRUITING
PanAmerican Clinical Research, Brownsville
NOT_YET_RECRUITING
Clinical Research Prime, Idaho Falls
RECRUITING
MedPharmics, Phoenix
NOT_YET_RECRUITING
Paradigm Clinical Research, La Mesa
Lead Sponsor
Meissa Vaccines, Inc.
INDUSTRY